Ozempic vs Wegovy: What's the Difference?

If you've been researching GLP-1 medications, you've almost certainly encountered both Ozempic and Wegovy. They're both semaglutide. They're both made by Novo Nordisk. They're both injected once weekly. So what's the actual difference?

The short answer: same molecule, different doses, different approved indications. But the details matter — especially if you're navigating insurance, costs, or trying to understand why your doctor prescribed one vs. the other.

The Core Difference: Indication and Dose

Ozempic (semaglutide) is FDA-approved for type 2 diabetes management. It helps lower blood sugar (HbA1c) and reduces cardiovascular risk in patients with established heart disease. The approved doses are 0.5 mg, 1.0 mg, and 2.0 mg once weekly.

Wegovy (semaglutide) is FDA-approved for chronic weight management in adults with: - BMI ≥ 30 (obesity), or - BMI ≥ 27 with at least one weight-related condition (hypertension, type 2 diabetes, sleep apnea, etc.)

Wegovy's maximum approved dose is 2.4 mg once weekly — higher than Ozempic's 2.0 mg ceiling.

So Ozempic goes up to 2.0 mg; Wegovy goes up to 2.4 mg. Same drug, different dose ceiling, different labeled indication.

Same Molecule — Different Trials, Different Approvals

Novo Nordisk ran separate clinical trial programs for each product. Ozempic's approval is grounded in the SUSTAIN trials (diabetes management and cardiovascular outcomes). Wegovy's approval is grounded in the STEP trials, specifically designed for obesity treatment.

The STEP 1 trial (the pivotal Wegovy trial) showed a mean weight loss of 14.9% of body weight at 2.4 mg over 68 weeks — significantly better than what was observed at lower doses in diabetes trials.

This isn't regulatory theater. The separation exists because the clinical evidence at 2.4 mg was built specifically for obesity treatment, and the FDA approves drugs for specific indications based on specific evidence packages.

Why Do People Use Ozempic Off-Label for Weight Loss?

Because it works — and it's often more accessible.

Ozempic's FDA indication is diabetes, but physicians can prescribe it off-label for weight management. Many patients without diabetes have been prescribed Ozempic for weight loss, particularly when Wegovy was in shortage (which it frequently has been).

The clinical reality: at doses of 1.0–2.0 mg, Ozempic produces meaningful weight loss. Not quite at Wegovy 2.4 mg levels, but often clinically significant. For patients who respond well to lower doses, Ozempic works perfectly well.

The reason the shortage of Wegovy became such a big story: enormous demand for semaglutide for weight loss, across both branded products, strained Novo Nordisk's manufacturing capacity.

The Price Problem

Both Ozempic and Wegovy carry sticker prices that are genuinely hard to stomach:

• Ozempic: Approximately $935–$1,000 per month without insurance
• Wegovy: Approximately $1,350–$1,500 per month without insurance

Insurance coverage varies dramatically. Ozempic is more commonly covered for patients with diagnosed type 2 diabetes. Wegovy coverage for obesity (without diabetes) is less consistent — many commercial plans don't cover it, and prior authorization requirements create significant friction.

Medicare Part D historically excluded weight loss medications, though this is changing slowly through legislative action.

Why Compounded Semaglutide Is Often the Better Option

For the vast majority of patients paying out of pocket, the branded price is prohibitive. This is where compounded semaglutide enters the picture.

Compounded semaglutide from an FDA-registered pharmacy can cost $100–$300 per month — a fraction of branded product pricing. The active molecule is the same: semaglutide. The titration protocol is the same.

Compounded versions don't carry the Ozempic or Wegovy brand names and aren't FDA-approved as finished drug products. They're prepared under pharmacy compounding regulations. However, during the period when semaglutide was on the FDA shortage list, compounding was legally authorized and widely used.

The practical advantages of the compounded route: - Dramatically lower cost - Telehealth-accessible (no specialist referral required) - Flexible dosing — prescribers can write for custom concentrations - Often includes clinical support from the telehealth platform

For patients without insurance coverage for weight management medications — which is the majority — compounded semaglutide through a telehealth platform like Marrow provides the same clinical benefit at a cost that doesn't require a second mortgage.

Which One Should You Ask About?

The clinical question is simpler than the branding:

• If you have type 2 diabetes and your insurer covers Ozempic: it's worth pursuing the branded route with your endocrinologist or PCP.
• If you're treating obesity without diabetes, cost is a concern, or you lack coverage: compounded semaglutide through a telehealth provider is the pragmatic choice for most people.
• If you want maximum approved dose (2.4 mg): that's Wegovy's territory — or a prescriber who doses compounded semaglutide to the same protocol.

Don't let brand names confuse the clinical picture. Ozempic and Wegovy are the same drug. The relevant variables are dose, indication, and cost — and a good prescriber will help you navigate all three.